← Parabilis Medicines, Inc. (PBLS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Parabilis Medicines, Inc. (PBLS)
Pharmaceutical Preparations · market cap $4.3B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Parabilis Medicines, Inc. (PBLS) is a ~145-employee clinical-stage biotechnology company with a market cap of approximately $3.7B and a single disclosed pipeline asset, FOG-001, currently in Phase 2 development for an undisclosed cancer indication via an undisclosed mechanism of action. The company's next major catalyst is an estimated Phase 2 data readout for FOG-001 around April 2027, rated 7/10 importance. Financial details including cash, runway, and dilution history are not publicly disclosed in the available facts.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2027-04-01 (est.)Phase 2 · FOG-001imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| FOG-001 | Phase 2 | Cancer |
Price & technical context
3-month
-1.6%
6-month
—
12-month
—
52-wk range
$25.01–$41.73
vs 50-day MA
-20.8%
vs 200-day MA
—
Realized vol
72.1%
Max drawdown
-31.2%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PBLS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.